{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:07Z","timestamp":1792017307859,"version":"4.4.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.mayocp.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T03:01:42Z","timestamp":1489201302000},"page":"578-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Therapy for Relapsed Multiple Myeloma"],"prefix":"10.1016","volume":"92","author":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib3","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib4","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib5","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.mayocp.2017.01.003_bib6","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1200\/JCO.2010.32.8435","article-title":"Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications","volume":"29","author":"Herv\u00e9","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A\u00a0practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4065\/mcp.2009.0677","article-title":"Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies","volume":"85","author":"Kapoor","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.mayocp.2017.01.003_bib11","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2017.01.003_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2017.01.003_bib15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2017.01.003_bib16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(14)70443-7","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mayocp.2017.01.003_bib18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/asheducation-2009.1.566","article-title":"How to treat elderly patients with multiple myeloma: combination of therapy or sequencing","author":"Palumbo","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib19","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib23","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.mayocp.2017.01.003_bib24","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2017.01.003_bib25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib27","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2017.01.003_bib28","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.mayocp.2017.01.003_bib29","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.mayocp.2017.01.003_bib36","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib and dexamethasone for multiple myeloma: CASTOR study","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2017.01.003_bib38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocp.2017.01.003_bib40","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"issue":"9513","key":"10.1016\/j.mayocp.2017.01.003_bib42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13296","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone and thalidomide versus melphalan, prednisone and lenalidomide (ECOG: E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.mayocp.2017.01.003_bib48","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.13100","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma","volume":"168","author":"Reece","year":"2015","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.mayocp.2017.01.003_bib51","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2017.01.003_bib52","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","article-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","volume":"124","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib54","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.mayocp.2017.01.003_bib55","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib56","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.mayocp.2017.01.003_bib57","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.01.003_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.V124.21.304.304","article-title":"Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM)","volume":"124","author":"Lacy","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.01.003_bib59","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V126.23.3036.3036","article-title":"A\u00a0phase 1, multicenter study of pomalidomide, bortezomib and low-dose dexamethasone in patients with proteasome inhibitor exposed and lenalidomide-refractory myeloma (trial MM-005)","volume":"126","author":"Richardson","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib60","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib61","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib62","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib64","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib65","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2014.118182","article-title":"Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study","volume":"100","author":"Moreau","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib66","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib68","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.mayocp.2017.01.003_bib69","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib70","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2017.01.003_bib71","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib72","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib73","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J\u00a0Card Fail"},{"issue":"24","key":"10.1016\/j.mayocp.2017.01.003_bib74","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10027","key":"10.1016\/j.mayocp.2017.01.003_bib75","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD(+)-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib77","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib78","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/trf.13474","article-title":"Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing","volume":"56","author":"De Vooght","year":"2016","journal-title":"Transfusion"},{"issue":"6 pt 2","key":"10.1016\/j.mayocp.2017.01.003_bib79","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"issue":"6 pt 2","key":"10.1016\/j.mayocp.2017.01.003_bib80","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib81","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib82","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib83","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2010.05.003","article-title":"The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma\u2014a report by the Polish Myeloma Study Group","volume":"34","author":"Dmoszynska","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib84","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A\u00a0comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma","volume":"156","author":"Khan","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib85","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.22053","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.mayocp.2017.01.003_bib86","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2017.01.003_bib87","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib89","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9594","key":"10.1016\/j.mayocp.2017.01.003_bib90","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2017.01.003_bib91","doi-asserted-by":"crossref","unstructured":"Hulin C, Belch A, Shustik C, et\u00a0al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial [published online ahead of print June 20, 2016]. J Clin Oncol. doi: 10.1200\/JCO.2016.66.7295.","DOI":"10.1200\/JCO.2016.66.7295"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib92","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2017.01.003_bib93","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","article-title":"Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM","volume":"127","author":"Mateos","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib95","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3109\/10428194.2012.664844","article-title":"Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed\/refractory multiple myeloma","volume":"53","author":"Offidani","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib96","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia","volume":"283","author":"Kyle","year":"1970","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib97","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2011.08887.x","article-title":"Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma","volume":"156","author":"Grey-Davies","year":"2012","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.mayocp.2017.01.003_bib98","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","article-title":"Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"160","author":"Berenson","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","article-title":"Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma","volume":"123","author":"Ludwig","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib101","first-page":"1096","article-title":"Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish\/PETHEMA trial","volume":"100","author":"Mateos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.mayocp.2017.01.003_bib102","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.mayocp.2017.01.003_bib104","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib106","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1535-7163.MCT-15-0488","article-title":"Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor","volume":"15","author":"Rosebeck","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib107","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14728214.2016.1186644","article-title":"Emerging antibodies for the treatment of multiple myeloma","volume":"21","author":"Zagouri","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib109","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.01.003_bib110","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib111","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.13171","article-title":"Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease","volume":"168","author":"Kort\u00fcm","year":"2015","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.mayocp.2017.01.003_bib112","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.mayocp.2017.01.003_bib114","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib115","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2017.01.003_bib116","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.mayocp.2017.01.003_bib117","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1038\/bcj.2016.15","article-title":"Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma","volume":"6","author":"Binder","year":"2016","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib118","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib119","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib120","first-page":"469","article-title":"Comparison of (18)F-FDG PET\/CT and PET\/MRI in patients with multiple myeloma","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib121","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.V88.5.1780.1780","article-title":"Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma","volume":"88","author":"Witzig","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib122","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/bjh.13067","article-title":"Quantification of clonal circulating plasma cells in relapsed multiple myeloma","volume":"167","author":"Gonsalves","year":"2014","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.mayocp.2017.01.003_bib123","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2011-03-342089","article-title":"Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.01.003_bib124","doi-asserted-by":"crossref","unstructured":"Periago A, Campillo JA, Mrowiec A, et\u00a0al. Circulating aberrant plasma cells allows risk stratification of patients with myeloma [published online ahead of print May 24, 2016]. Am J Hematol. doi: 10.1002\/ajh.24431.","DOI":"10.1002\/ajh.24431"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","article-title":"Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients","volume":"94","author":"An","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib126","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.mayocp.2017.01.003_bib127","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib128","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/leu.2009.273","article-title":"Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","volume":"24","author":"Avet-Loiseau","year":"2010","journal-title":"Leukemia"},{"issue":"30","key":"10.1016\/j.mayocp.2017.01.003_bib129","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib130","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.25775","article-title":"Chromosomal aberrations\u00a0+1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone","volume":"117","author":"Klein","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib131","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"Chang","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.12223","article-title":"Cytogenetics of extramedullary manifestations in multiple myeloma","volume":"161","author":"Billecke","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib133","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib134","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bmt.2014.237","article-title":"Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents","volume":"50","author":"Jimenez-Zepeda","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib135","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib136","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.mayocp.2017.01.003_bib137","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2017.01.003_bib138","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib139","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2017.01.003_bib140","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.mayocp.2017.01.003_bib141","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.mayocp.2017.01.003_bib142","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib143","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2015.125864","article-title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"100","author":"San Miguel","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib144","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"10.1016\/j.mayocp.2017.01.003_bib145","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mayocp.2017.01.003_bib146","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3109\/10428194.2013.784971","article-title":"Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma","volume":"54","author":"Gertz","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib147","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1702445","article-title":"Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma","volume":"26","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib148","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib149","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib150","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2011.04.005","article-title":"Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry","volume":"17","author":"Cook","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib151","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2012.751528","article-title":"Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma","volume":"54","author":"Dunavin","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.mayocp.2017.01.003_bib152","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bmt.2012.183","article-title":"Second auto-SCT for treatment of relapsed multiple myeloma","volume":"48","author":"Gonsalves","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib153","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.mayocp.2017.01.003_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.04.004","article-title":"Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation","volume":"62","author":"Merz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib155","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib156","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib157","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2014.27","article-title":"Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy","volume":"28","author":"Berenson","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.mayocp.2017.01.003_bib158","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.4161\/cc.9.18.13047","article-title":"Evolutionary dynamics of two related malignant plasma cell lines","volume":"9","author":"Dingli","year":"2010","journal-title":"Cell Cycle"},{"issue":"21","key":"10.1016\/j.mayocp.2017.01.003_bib159","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.V120.21.73.73","article-title":"Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma\u2014data from a dose-escalation phase I\/II study","volume":"120","author":"Plesner","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2017.01.003_bib160","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib161","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2017.01.003_bib162","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib163","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.01.003_bib164","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.01.003_bib165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, Phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib166","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.01.003_bib167","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2017.01.003_bib168","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib169","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.mayocp.2017.01.003_bib171","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib172","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.mayocp.2017.01.003_bib173","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.mayocp.2017.01.003_bib174","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib175","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-0609.2005.00531.x","article-title":"Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma","volume":"75","author":"Terpos","year":"2005","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib176","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/10428194.2014.893304","article-title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia","volume":"56","author":"Jimenez-Zepeda","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.mayocp.2017.01.003_bib177","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.leukres.2009.01.036","article-title":"Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?","volume":"33","author":"Katodritou","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib178","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.23600","article-title":"Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek\u00a0myeloma study group","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib179","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/DAD.0b013e31826d729f","article-title":"Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis","volume":"35","author":"Comfere","year":"2013","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.01.003_bib180","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib181","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2017.01.003_bib182","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0609.2011.01629.x","article-title":"Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?","volume":"87","author":"Jimenez-Zepeda","year":"2011","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib183","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gcc.20670","article-title":"Frequent upregulation of MYC in plasma cell leukemia","volume":"48","author":"Chiecchio","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib184","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.mayocp.2017.01.003_bib185","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.01.003_bib186","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/10428190902803644","article-title":"Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"50","author":"Costa","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.mayocp.2017.01.003_bib187","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clml.2015.03.016","article-title":"Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic","volume":"15","author":"Mir","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.mayocp.2017.01.003_bib188","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11899-008-0015-9","article-title":"Role of allogeneic stem cell transplantation in multiple myeloma","volume":"3","author":"Kumar","year":"2008","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.mayocp.2017.01.003_bib189","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617300289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617300289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T18:53:14Z","timestamp":1601751194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617300289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0025619617300289"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.01.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for Relapsed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}